Monoamine oxidase A gene polymorphism, 5-HT2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine

Neuropsychobiology

Volumn 48, Issue 1, 2003, Pages 10-13

  Yoshida, Keizo ^a   Naito, Shingo ^a   Takahashi, Hitoshi ^a   Sato, Kazuhiro ^a   Ito, Kenichi ^a   Kamata, Mitsuhiro ^a   Higuchi, Hisashi ^a   Shimizu, Tetsuo ^a   Itoh, Kunihiko ^b   Inoue, Kazuyuki ^b   Suzuki, Toshio ^b   Ohkubo, Tadashi ^c  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 HT2A receptor; Fluvoxamine; Genetic polymorphism; Major depressive disorder; Monoamine oxidase A; Nausea

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BROTIZOLAM; FLUVOXAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NAUSEA; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL ANALYSIS;

ADULT; AGED; ALANINE; ANALYSIS OF VARIANCE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOTYPE; GLYCINE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINISATELLITE REPEATS; MONOAMINE OXIDASE; NAUSEA; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN ANTAGONISTS;

EID: 0041672538     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071822     Document Type: Article

References (17)

1. Spigset O: Adverse reactions of selective serotonin reuptake inhibitors: Reports from a spontaneous reporting system. Drug Saf 1999;20:277-287.
2. Wilde MI, Plosker GL, Benfield P: Fluvoxamine: An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46:895-924.
3. Takahashi H, Yoshida K, Ito K, Sato K, Kamata M, Higuchi H, Shimizu T, Ito K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K: No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002;12:477-481.
4. Hartter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C: Serum concentrations of fluvoxamine and clinical effects: A prospective open clinical trial. Pharmacopsychiatry 1998;31:199-200.
5. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
6. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
7. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Association between - 1438G/A promoter polymorphism in the 5-HT2A receptorgene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136-140.
8. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Monoamine oxidase A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1279-1283.
9. Shimoyama R, Ohkubo T, Sugawara K, Otani K, Yoshida K, Higuchi H, Shimizu T: Plasma level monitoring of fluvoxamine ans fluvoxam-ino acid in depression patients by new developed HPLC method (abstract). Int Clin Psychopharmacol 2002;17:s85.
10. Buchner A, Faul F, Erdfelder E: G·Power: A priori, post-hoc, and compromise power analyses for the Macintosh (version 2.1.1) [Computer program]. Trier, University of Trier, 1996.
11. Sabol SZ, Hu S, Hamer D: A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998;103:273-279.
12. Jönsson EG, Norton N, Gustavsson JP, Oreland L, Owen MJ, Sedvall GC: A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res 2000;34:239-244.
13. Cooper JR, Bloom FE, Roth RH: Serotonin (5-hydroxytryptamine and histamine); in: The Biochemical Basis of Neuropharmacology. New York, Oxford University Press, 1996, pp352-409.
14. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E: Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002;110:1-7.
15. Bergeron R, Blier P: Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 1994;151:1084-1086.
16. 3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol 1995;9:137-141.
17. Kasper S, Fuger J, Moller HJ: Comparative efficacy of antidepressants. Drugs 1992;43 (suppl 2):11-22; discussion 22-23.